deltatrials

Recurrent uterine corpus carcinoma Trials in Indianapolis, United States

Conditions / Recurrent uterine corpus carcinoma / Indianapolis, United States

Recurrent uterine corpus carcinoma has been the subject of sustained clinical investigation across multiple research sites.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID Title Status Phase
NCT01642082 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer COMPLETED PHASE2
NCT01210222 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer COMPLETED PHASE2
NCT01132820 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer COMPLETED PHASE2
NCT02065687 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer UNKNOWN PHASE2/PHASE3
NCT00897442 Collecting Tumor Samples From Patients With Gynecological Tumors COMPLETED
NCT00820898 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer COMPLETED PHASE2
NCT01225887 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer COMPLETED PHASE2
NCT01011933 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer COMPLETED PHASE2
NCT00063999 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer COMPLETED PHASE3
NCT00729586 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer COMPLETED PHASE2

Related Pages